These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12716775)

  • 1. Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.
    Griggs DJ; Marona H; Piddock LJ
    J Antimicrob Chemother; 2003 Jun; 51(6):1403-7. PubMed ID: 12716775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
    Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
    Yoon EJ; Lee CY; Shim MJ; Min YH; Kwon AR; Lee J; Choi EC
    Chemotherapy; 2010; 56(2):153-7. PubMed ID: 20407243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.
    Noguchi N; Okihara T; Namiki Y; Kumaki Y; Yamanaka Y; Koyama M; Wakasugi K; Sasatsu M
    Int J Antimicrob Agents; 2005 May; 25(5):374-9. PubMed ID: 15848290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
    Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
    J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations.
    Roychoudhury S; Twinem TL; Makin KM; Nienaber MA; Li C; Morris TW; Ledoussal B; Catrenich CE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3422-6. PubMed ID: 11709318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a high-density oligonucleotide array for characterization of grlA, grlB, gyrA and gyrB mutations in fluoroquinolone resistant Staphylococcus aureus isolates.
    Couzinet S; Yugueros J; Barras C; Visomblin N; Francois P; Lacroix B; Vernet G; Lew D; Troesch A; Schrenzel J; Jay C
    J Microbiol Methods; 2005 Feb; 60(2):275-9. PubMed ID: 15590102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY; Trucksis M; Hooper DC
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis.
    Peterson ML; Rotschafer JC; Piddock LJ
    J Antimicrob Chemother; 2003 Sep; 52(3):481-4. PubMed ID: 12917248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
    Lei Y; Gui X; Feng G
    Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):176-9. PubMed ID: 11798575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
    J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
    Kim JM; Kim JS; Kim N; Jung HC; Song IS
    J Antimicrob Chemother; 2005 Nov; 56(5):965-7. PubMed ID: 16159928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.